HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Studying MGUS and Smoldering Myeloma Genetics and Using Immunotherapies in High-Risk Smoldering Myeloma with Dr. Elisabet Manasanch, MD Anderson Cancer Center
Studying MGUS and Smoldering Myeloma Genetics and Using Immunotherapies in High-Risk Smoldering Myeloma with Dr. Elisabet Manasanch, MD Anderson Cancer Center image
HealthTree Podcast for Multiple Myeloma
event Apr 26, 2017 / 11:00AM - 12:00PM MDT

Event Description

Elisabet Manasanch, MD MD Anderson Cancer Center Interview Date: April 26, 2017 

MGUS and smoldering myeloma are precursor conditions to multiple myeloma. For those with the early markers, who will progress and who will not? Dr. Elisbet Manasanch at MD Anderson Cancer Center is using myeloma genetics testing to help determine answers to this important question. Dr. Manasanch describes a study she has open to test MGUS and smoldering myeloma patients using a test called the GEP-70, a gene expression profile test and observe the way that their disease potentially changes over time. The answers to this study will help myeloma specialists know how to segment patients into different groups and identify who may benefit from early treatment. She also describes a study open at MD Anderson for high-risk smoldering myeloma patients using a monoclonal antibody called Isatuximab.  To find the two clinical trials discussed in this show, click here: Isatuximab Clinical Trial for High-Risk Smoldering Myeloma   MGUS and Smoldering Myeloma Genomics Study To find all clinical trials at MD Anderson Cancer Center, click here: MD Anderson Myeloma Clinical Trials Dr. Elisabet Manasanch on Myeloma Crowd Radio

Schedule & Agenda

person
Discussion
11:00AM
Dr. Elisabet Manasanch & Jenny Ahlstrom

Speakers & Moderators

The panelist Elisabet Manasanch, MD
Elisabet Manasanch, MD

Dr. Manasanch specializes in the treatment of patients with multiple myeloma. Furthermore, she focuses on translational research of the precursor stages of myeloma and early disease management through groundbreaking immunotherapy-focused clinical trials.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube